Company profile

Lexeo Therapeutics, Inc.

Pipeline7 assets

LX2006LX2006 / FXN / AAV gene therapy / Cardiovascular
Friedreich's ataxia (FA) cardiomyopathy
LX2020LX2020 / PKP2 / AAV gene therapy / Cardiovascular
PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM)
LX2021LX2021 / Cx43 / AAV gene therapy / Cardiovascular
DSP (Desmoplakin) cardiomyopathyDilated cardiomyopathy
LX2022LX2022 / TNNI3 / AAV gene therapy / Cardiovascular
Hypertrophic cardiomyopathy (HCM)
LX1001LX1001 / APOE2 / AAV gene therapy / Neurology
APOE4-associated Alzheimer's disease
LX1021LX1021 / Christchurch-modified APOE2 / AAV gene therapy / Neurology
APOE4-associated Alzheimer's disease
LX1020LX1020 / APOE2 / APOE4 (miRNA) / AAV gene therapy / Neurology
APOE4-associated Alzheimer's disease

Latest news11 items

Oct 1, 2026

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study Presentation will include new mFARS subscore analyses

Presentation / Abstract • Phase 1/2Oral presentation Wed, Oct 7, 2026, 12:30 PM KST

Sep 23, 2026

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum

Sep 22, 2026

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated

Sep 2, 2026

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in

Aug 12, 2026

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment

Trial Start • Phase 3Trial initiation Mon, Jun 1, 2026

Aug 5, 2026

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc.

Jun 17, 2026

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027 NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Lexeo

Trial Results • Phase 1/2JAMA Cardiology publication Wed, Jun 17, 2026

Jun 15, 2026

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

Trial Start • Phase 3Trial initiation Tue, Jun 30, 2026

May 19, 2026

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the 2026 RBC Capital Markets

May 11, 2026

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform to be presented at ASGCT 2026

Apr 27, 2026

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platform NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Presentation / Abstract • Phase 1/2